Novartis Pharma AG: New long-term Rhapsido (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)

Novartis announced 52-week Phase III data for Rhapsido (remibrutinib) in chronic inducible urticaria (CIndU), showing sustained efficacy and a consistent safety profile. The study met primary endpoints, with significant response rates in SD, ColdU, and CholU subtypes. Novartis plans additional regulatory submissions based on these results.

Original reporting
Published Nov 12, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 6:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NVS
Bullish
high confidence
Mentioned
$NVS
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The data could expand Rhapsido's label, increase sales potential, and boost Novartis' immunology franchise.

02

Market read

First‑report Phase III results are material for Novartis' valuation and may trigger short‑term buying pressure.

03

What to watch

Potential reimbursement challenges and the need for larger Phase III confirmatory studies could temper upside.

Relevance 7/10Novelty 9/10Timing: today

Background

Novartis announced the first long‑term efficacy data from its RemIND Phase III trial of Rhapsido in chronic inducible urticaria, a condition affecting ~0.5% of the population.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

Novartis released 52‑week Phase III data for Rhapsido (remibrutinib) showing sustained efficacy and safety in chronic inducible urticaria.

Expected impact

potential upside as investors price in expanded indication and upcoming regulatory submissions

Evidence & confidence

Data demonstrate strong response rates across subtypes and a favorable safety profile, supporting further approvals and market expansion.

Market effects

Strengthens the broader biotech/immune‑modulating sector as a successful BTK inhibitor may set a precedent for similar therapies.

Positive for European and US pharma markets where Novartis is a major component.

Adds to global pipeline confidence for chronic urticaria treatments.

Counterpoint

If regulatory hurdles delay approval or competition intensifies, the data may be priced out quickly.

Key entities

  • Novartis Pharma AG

    Swiss multinational pharmaceutical company developing Rhapsido.

  • Rhapsido (remibrutinib)

    Oral BTK inhibitor targeting chronic inducible urticaria.

Related articles

$NVSMed

Novartis CEO Warns US-China Biotech Curbs

Novartis CEO Vas Narasimhan warned on Bloomberg TV that US-China biotech curbs could limit technology exchange, hindering R&D and market access. The Treasury Department proposed including biotech in investment limits for foreign adversaries, affecting multinational drugmakers like Novartis. Restrictions may slow drug development and access to key markets.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.